According to criteria laid down by the Committee for Medicinal Products for Human Use (CHMP), a prepandemic vaccine needs to bring about protective levels of antibodies in at least 70% of people for it to be considered suitable.
Inimravimite komitee kriteeriumide kohaselt võib pre- pandeemilist vaktsiini pidada sobivaks, kui see kutsub esile antikehade kaitsva taseme vähemalt 70% - l inimestest.